[英文，研究]Quantitative HBV surface & e antigen titers

StephenW

Hepatology. 2011 May;53(5):1486-93. doi: 10.1002/hep.24221.

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers
in prediction of treatment response to entecavir.

Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, Hwang SG, Rim KS, Chon
CY, Han KH, Park JY.

Source
Department of Internal Medicine, Yonsei University College of Medicine,
Seoul, Korea; Department of Internal Medicine, CHA University, Seongnam-Si,
Korea.

Abstract
Quantitative hepatitis B surface antigen (qHBsAg) and quantitative
hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for
measuring viral loads and for predicting the virological response (VR) and
serological response (SR) to pegylated interferon therapy. However, the
clinical utility of these assays in patients taking entecavir (ETV) is
largely unknown. Treatment-naive patients with chronic hepatitis B (CHB)
who were taking ETV for 2 years were enrolled. The qHBsAg and qHBeAg levels
were serially measured with the Architect assay. From 95 patients, 60.0% of
whom were hepatitis B e antigen-positive [HBeAg(+)], 475 samples were
analyzed. The median baseline log hepatitis B virus (HBV) DNA, log qHBsAg,
and log qHBeAg values were 6.73 copies/mL (4.04-9.11 copies/mL), 3.58 IU/mL
(1.17-5.10 IU/mL), and 1.71 Paul Ehrlich (PE) IU/mL (-0.64 to 2.63 PE
IU/mL), respectively. For the prediction of VR (HBV DNA < 60 copies/mL at
24 months) in HBeAg(+) patients, baseline alanine aminotransferase (P =
0.013), HBV DNA (P = 0.040), and qHBsAg levels (P = 0.033) were
significant. For the prediction of VR, the area under the curve for the
baseline log qHBsAg level was 0.823 (P < 0.001); a cutoff level of 3.98
IU/mL (9550 IU/mL on a nonlogarithmic scale) yielded the highest predictive
value with a sensitivity of 86.8% and a specificity of 78.9%. As for SR
(HBeAg loss at 24 months), the reduction of qHBeAg was significantly
greater in the SR(+) group versus the SR(-) group. The sensitivity and
specificity were 75.0% and 89.8%, respectively, with a decline of 1.00 PE
IU/mL at 6 months. With ETV therapy, the correlation between HBV DNA and
qHBsAg peaked at 6 months in HBeAg(+) patients. Conclusion: Both qHBsAg and
qHBeAg decreased significantly with ETV therapy. The baseline qHBsAg levels
and the on-treatment decline of qHBeAg in HBeAg(+) patients were proven to
be highly useful in predicting VR and SR, respectively. The determination
of qHBsAg and qHBeAg can help us to select the appropriate strategy for the
management of patients with CHB. However, the dynamic interplay between
qHBsAg, qHBeAg, and HBV DNA during antiviral therapy remains to be
elucidated. (Hepatology 2011;).

Copyright © 2011 American Association for the Study of Liver Diseases.

PMID: 21520167 [PubMed - in process]



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

lin12345

乙型肝炎表面抗原定量和乙肝e抗原滴度
在恩替卡韦治疗反应的预测。

李谟，安上海，金协，公园小时，张兴业，金道Ÿ，黄法兴，环堪萨斯州，骏
赛扬，韩因次周波数kh，公园枝。

来源
内科部，延世大学医学院，
汉城;内科，查大学城南市部，
韩国。

摘要
乙肝表面抗原定量（qHBsAg）和定量
B型肝炎e抗原（qHBeAg）滴度正在成为有用的工具
病毒载量的测量和预测的病毒学应答（VR）和
血清学反应（简），以聚乙二醇干扰素治疗。然而，
恩替卡韦的临床应用患者服用这些化验（教育电视）是
知之甚少。慢性乙型肝炎（CHB）治疗初治患者
谁服用2年，教育电视的患者。水平的qHBsAg和qHBeAg
分别连续测量与建筑师法。从95例，60.0％的
人是B型肝炎e抗原阳性[e抗原(+)], 475样本
分析。日志中位数基准乙型肝炎病毒（HBV）的DNA，日志qHBsAg，
和日志qHBeAg值分别为6.73拷贝/毫升（4.04-9.11拷贝/毫升），3.58国际单位/毫升
（1.17-5.10国际单位/毫升），和1.71保罗埃利希（PE）的国际单位/毫升（-0.64至2.63体育
国际单位/毫升），分别为。对于虚拟现实预测（乙肝病毒脱氧核糖核酸<60拷贝/毫升的
24个月）在HBeAg（+）患者，基线丙氨酸转氨酶（P值
0.013），乙肝病毒脱氧核糖核酸（P值0.040），和qHBsAg水平（P = 0.033）是
显着。对于虚拟现实，曲线下面积为预测
基线水平为0.823日志qHBsAg性（P“0.001）;水平的3.98截止
国际单位/毫升（9550国际单位/毫升规模上nonlogarithmic）产生的最高的预测
值的86.8％的敏感性和特异性78.9％。至于简
（e抗原在24个月亏损），减少了qHBeAg显着
更大的SR（+）与组的SR（ - ）组。的敏感性和
特异性分别为75.0％和89.8％，分别下降了1.00体育
国际单位/毫升在6个月。随着教育电视的治疗，乙肝病毒DNA和相关性之间
qHBsAg高峰在6个月在HBeAg（+）患者。结论：qHBsAg和
qHBeAg与教育电视治疗显着降低。基线qHBsAg水平
和e抗原qHBeAg（+）被证明患者待遇下降
高度虚拟现实和SR的预测，分别有用。决心
对qHBsAg和qHBeAg可以帮助我们选择合适的策略，为
慢性乙型肝炎患者的管理。然而，动态之间的相互作用
qHBsAg，qHBeAg，并在抗病毒治疗的乙肝病毒DNA的仍是
阐明。 （杂志2011年）。

版权©为2011年美国肝病研究协会。

结论：21520167 [PubMed的 - 过程]

新! 点击上方的字词即可查看其他翻译。 删除